Phillips, D J <br/><br/>
Release of activin and follistatin during cardiovascular procedures is largely due to heparin administration.  [electronic resource] 

 -  The Journal of clinical endocrinology and metabolism  Jul 2000 
 - 2411-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0021-972X 
<br/><br/><label>Standard No.: </label>10.1210/jcem.85.7.6666  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Activins<br/>Aged<br/>Aged, 80 and over<br/>Anticoagulants--adverse effects<br/>Aortic Aneurysm, Abdominal--surgery<br/>Cardiovascular Surgical Procedures--adverse effects<br/>Coronary Angiography<br/>Endarterectomy, Carotid<br/>Female<br/>Follistatin<br/>Glycoproteins--metabolism<br/>Growth Substances--metabolism<br/>Heparin--adverse effects<br/>Humans<br/>Inhibins--metabolism<br/>Interleukin-1--metabolism<br/>Male<br/>Middle Aged<br/>Time Factors